Platelets >= 50,000/mcL or recovery to the baseline countXx_NEWLINE_xXPARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Platelets: > 50,000/mcL, within 2 weeks prior to enrollmentXx_NEWLINE_xXPlatelets >= 60,000 cells/mm^3; obtained within 14 days prior to study entryXx_NEWLINE_xXPlatelets (PLT) > 150,000/mm^3Xx_NEWLINE_xXPlatelets >= 50,000/mm^3 (without support)Xx_NEWLINE_xXPlatelets >= 30,000/mm^3Xx_NEWLINE_xXObtained within 28 days prior to registration: Platelets >= 50,000/mclXx_NEWLINE_xXPlatelets >= 50,000 cells/mm^3Xx_NEWLINE_xXPlatelets >= 50,000/mcl within 28 days prior to registrationXx_NEWLINE_xXPlatelets >= 70,000 cells/mm^3, within 21 days prior to study entryXx_NEWLINE_xXWithin 10 days of treatment initiation: Platelets >= 50,000 cells/mm^3Xx_NEWLINE_xXPlatelets >= 100,000/mm^3, or >= 50,000 in cases of ongoing bone marrow involvement (in either case, these must be independent of transfusion support), documented within 14 days of registrationXx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets ? 50,000/mm3Xx_NEWLINE_xXPlatelets >= 75,000/mcL (>= 50,000 for patients with hematologic malignancies)Xx_NEWLINE_xXPlatelets (Plt) >= 30,000 x 10^9/LXx_NEWLINE_xXPlatelets >= 150,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mcl (documented within 28 days of registration)Xx_NEWLINE_xXObtained =< 21 days prior to registration: platelets (PLT) >= 50,000/uLXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXEXPANDED ACCESS COHORT: Platelets >= 50,000/mcLXx_NEWLINE_xXPlatelets >= 25,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mm^3\r\n* Exception: unless documented bone marrow involvement by lymphomaXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets > 50,000/mm3,Xx_NEWLINE_xXPlatelets >= 50,000/uL; a subject will not be excluded because of pancytopenia related to diseaseXx_NEWLINE_xXINCLUSION - TREATMENT: Platelets > 50,000/ulXx_NEWLINE_xXPlatelets >/= 30,000/mm3Xx_NEWLINE_xXPlatelets >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50% or >= 30,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50%, obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelets > 80,000 compatible for surgeryXx_NEWLINE_xXPlatelets ? 50,000/mm^3 independent of transfusion support, with no active bleedingXx_NEWLINE_xXPlatelets >= 30,000/mm^3Xx_NEWLINE_xXPlatelets > 50,000/uL.Xx_NEWLINE_xXPlatelets: >= 100,000/mm^3 or >= 50,000/mm^3 if known or suspected bone marrow involvement, independent of transfusion support in either situationXx_NEWLINE_xXPlatelets ? 50,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 150,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets ? 50,000/mm^3Xx_NEWLINE_xXPlatelets >= 20,000/mm^3Xx_NEWLINE_xXPatients with blood or platelet transfusion within 1 week prior to signing Consent A, or with platelets < 50,000/mm^3, neutrophils < 750/mm^3, or hemoglobin < 8.5 g/dL, unless the cytopenias are considered by the treating physician to be largely due to marrow involvement by lymphomaXx_NEWLINE_xXWithin 7-10 days of study drug administration: Platelets >= 90,000/mm^3Xx_NEWLINE_xX+ 0 for (platelets <50), +1 for (platelets >50).Xx_NEWLINE_xXPlatelets >= 50,000/mcL; >= 25,000/mcL if impairment is due to LPD/NHL (transfusions not permitted)Xx_NEWLINE_xXPlatelets >= 50,000/mcL (transfusions not permitted)Xx_NEWLINE_xXObtained within 21 days of registration: platelets > 50,000/mcLXx_NEWLINE_xXPlatelets >= 80,000/mcLXx_NEWLINE_xXPlatelets >= 80,000 x 10^9/L unsupported by transfusions (within 14 days of study registration)Xx_NEWLINE_xXPlatelet counts of >= 100,000 cells/mm^3 for patients who have bone marrow plasmacytosis of < 50%, or platelets >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50%Xx_NEWLINE_xXPlatelets >= 150,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets > 10 x 10^9/LXx_NEWLINE_xXPlatelets >= 25,000/mcLXx_NEWLINE_xXPlatelets >= 25,000/mcLXx_NEWLINE_xXPlatelets >= 90,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mcl; transfusion and/or growth factor are permitted within any timeframeXx_NEWLINE_xXPlatelet count >/=50,000 cells/mcL, or >/=30,000 cells/mcL if more than 50% bone marrow involvement (Cohorts A, B, D, E, F)Xx_NEWLINE_xXFOR AML ONLY: Obtained =< 14 days prior to registration: PLT >= 10,000/uL (transfusion to get platelets >= 10,000 is allowed)Xx_NEWLINE_xXObtained =< 14 days prior to registration: Platelets >= 50,000 cells/mm^3 for patients who have bone marrowXx_NEWLINE_xXTo be performed within 10 business days prior to day 1: Platelets >= 50,000/mm^3; NOTE: platelet transfusion and packet red blood cell transfusion can be given prior to enrollment to achieve a target platelet (Plt) >= 50,000/uL and hemoglobin of >= 8.5 g/dLXx_NEWLINE_xXPlatelets >= 50,000/mm^3 independent of transfusion support, with no active bleedingXx_NEWLINE_xXPlatelets > 50,000/mm^3Xx_NEWLINE_xXPlatelets >= 80 x 10^9/LXx_NEWLINE_xXPlatelets greater than or equal to 50,000 mcLXx_NEWLINE_xXPlatelets =< 50,000Xx_NEWLINE_xXPlatelets: >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement independent of transfusion support in either situationXx_NEWLINE_xXPlatelets >= 100 x 10^9/L:\r\n* Unless due to bone marrow infiltration then eligible if platelets > 50 x 10^9/L)Xx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 60,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mcl, obtained within 14 days of first dose of drugXx_NEWLINE_xXPlatelets (PLT) < 50,000 K/mcLXx_NEWLINE_xXPatients must have platelets (plt) >= 50,000/uL; platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and during treatment to achieve a target plt >= 50,000/uL provided that patients have not received growth factors for at least 14 days prior to entering trialXx_NEWLINE_xXPlatelets >= 50 x 10^9/L (without transfusion support)Xx_NEWLINE_xXPlatelets >= 150,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mcL (transfusion independent)Xx_NEWLINE_xXPlatelets >= 50,000/mclXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets >= 50.000/mcLXx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 80K/mm^3Xx_NEWLINE_xXPlatelets < 50,000/mclXx_NEWLINE_xXPlatelets >= 80,000/mcLXx_NEWLINE_xXPlatelet count >= 50,000/?l (>= 30,000/?l if bone marrow plasma cells are >= 50% of cellularity)Xx_NEWLINE_xXPlatelets >= 50 x10^9 (SI units 10^9/L)Xx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets >= 50,000/mm^3 or >= 30,000/mm^3 in the setting of marrow involvement by disease or splenomegaly due to disease (independent of growth factor or transfusion support)Xx_NEWLINE_xXPlatelet > 50,000 mcLXx_NEWLINE_xXPlatelets ? 150,000 x 10^6 cells/LXx_NEWLINE_xXDocumented platelets >= 80,000Xx_NEWLINE_xXPlatelets >= 80 x 10^9/LXx_NEWLINE_xXPlatelets > 50,000/cu mm (transfusion allowed - however patients must not require more than two platelet transfusions per week)Xx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mm^3 or >= 30,000/mm^3 in the setting of marrow involvement by disease or splenomegaly due to diseaseXx_NEWLINE_xXPlatelets >= 50 x 10^9/LXx_NEWLINE_xXPlatelets >= 50,000/mclXx_NEWLINE_xXPlatelets >= 50,000 x 10^9/LXx_NEWLINE_xXPlatelets >= 50 x K/uLXx_NEWLINE_xXPlatelets are >= 50,000/mm^3Xx_NEWLINE_xXPlatelets >= 90,000/mcLXx_NEWLINE_xXPatients with coagulopathy with an elevated INR ?1.5, or platelets <50Xx_NEWLINE_xXPlatelets > 125,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mclXx_NEWLINE_xXPlatelets >= 50,000 X 10^9 /L without transfusion if stem cells are not availableXx_NEWLINE_xXPlatelets >= 20,000 X 10^9 /L with transfusions allowed if stem cells availableXx_NEWLINE_xXPlatelets > 50 k/ulXx_NEWLINE_xXPlatelets >= 50 x 10^9/LXx_NEWLINE_xXPlatelets > 50,000/uLXx_NEWLINE_xXPlatelets more or equal to 50,000/mLXx_NEWLINE_xXPlatelets >= 50,000/mLXx_NEWLINE_xXPlatelets >= 20 K/mcLXx_NEWLINE_xXPlatelets >= 80,000/mm^3; this value must be obtained within four weeks before protocol entryXx_NEWLINE_xXThrombocytopenia (< 125,000 platelets/mm^3)Xx_NEWLINE_xXPlatelets > 50 x 10^9/L without transfusion in the prior 7 daysXx_NEWLINE_xXPlatelets ? 75,000/mcL OR ? 50.000 if thrombocytopenia due to iBCLXx_NEWLINE_xXPlatelets > 50 x 10^9/LXx_NEWLINE_xXPlatelets ? 40,000/mm^3Xx_NEWLINE_xXPlatelets < 75000/mm^3.Xx_NEWLINE_xXPlatelets >= 50,000 cells/mm^3Xx_NEWLINE_xXPlatelets >= 50,000 cells/mm^3 if marrow plasmacytosis < 50% OR platelet count >= 30,000 cells/mm^3 if marrow plasmacytosis >= 50%Xx_NEWLINE_xXPlatelets >= 120,000/mm^3Xx_NEWLINE_xXPlatelets >= 10 x 10^9/LXx_NEWLINE_xXPlatelets >= 30,000/mm^3Xx_NEWLINE_xXPlatelets >= 80,000 x 10^9/L, unsupported by transfusionsXx_NEWLINE_xXPlatelets ?10,000/mm3 with no active bleedingXx_NEWLINE_xXPlatelets > 50,000/ulXx_NEWLINE_xXPlatelets > 50,000/uLXx_NEWLINE_xXPlatelets >= 75,000/mcL\r\n* Patients whose platelets are >= 50,000/mcL will be allowed on trial if low platelet count is due to lymphomaXx_NEWLINE_xXPlatelets >= 50,000 cells/mcL (50 x 10^9/L)Xx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets less than 50 x 10^3/mm^3Xx_NEWLINE_xXPlatelets >= 75,000 / mcL if no bone marrow involvement, platelets >= 50,000 / mcL if documented bone marrow involvementXx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets > 150,000Xx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets > 50,000 per microliterXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets >= 50 x 10^9/LXx_NEWLINE_xXPlatelets >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50% or >= 30,000 cells/mm^3 for patients who have bone marrow plasmacytosis of >= 50% within 14 days prior to registrationXx_NEWLINE_xXPlatelets >= 50,000Xx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets ? 50.000//mm3Xx_NEWLINE_xXPlatelets > 50,000/mcLXx_NEWLINE_xXMF PATIENTS: Platelets >= 50,000/mm^3; Note: this must be achieved without transfusionXx_NEWLINE_xXPlatelets ? 50,000/mm3Xx_NEWLINE_xXPlatelet count > 50,000 cells/mcL (50 × 10^9/L)Xx_NEWLINE_xXPlatelets >= 50,000/mclXx_NEWLINE_xXPlatelets > 90 x 10^9/LXx_NEWLINE_xXPlatelets ? 60 x 109/L.Xx_NEWLINE_xXPlatelets >= 90,000/mm^3Xx_NEWLINE_xXPlatelets < 100x109/LXx_NEWLINE_xXPlatelets >= 50,000 /mm^3Xx_NEWLINE_xXObtained within 30 days of registration: Platelets >= 75,000/mcL or >= 50,000/mcL with documented bone marrow involvementXx_NEWLINE_xXPart 1: platelets >= 75,000/mcl; Part 2: platelets >= 50,000/mcl if there is bone marrow involvement by lymphoma; platelets >= 75,000/mcl if there is no bone marrow involvementXx_NEWLINE_xXPlatelets >= 100 x 10^9/L or >= 50 x 10^9/L (if related to lymphoma)Xx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPrior to cyclophosphamide and T cell infusions: platelets =< 50,000Xx_NEWLINE_xXPlatelets > 50 K/mcLXx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 200 x 10^9/LXx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets >= 20,000 without platelet transfusionXx_NEWLINE_xXPlatelets < 50,000 x 10^9/L.Xx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets >= 40,000/mm^3Xx_NEWLINE_xXPlatelets < 50,000/ulXx_NEWLINE_xXPlatelets >50000 cells/mm3Xx_NEWLINE_xXPlatelets > 50,000/mm^3 without growth factors or transfusionsXx_NEWLINE_xXPlatelets (PLT) >= 50,000 mLXx_NEWLINE_xXPlatelets >= 50,000/mcL without growth factors or transfusionsXx_NEWLINE_xXPlatelets >= 160 x 10^9/LXx_NEWLINE_xXObtained =< 21 days prior to registration: Platelets (PLT) >= 50,000/uLXx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 50,000 cells/uL within 14 days before enrollmentXx_NEWLINE_xXAT THE TIME OF INFUSION: Platelets > 50,000/ulXx_NEWLINE_xXPlatelets >= 50,000/ mm^3Xx_NEWLINE_xXPlatelets >= 80,000/mcLXx_NEWLINE_xXPlatelets =< 50,000Xx_NEWLINE_xXPlatelets > 50,000/mcLXx_NEWLINE_xXPlatelets >= 75,000 total (>= 50,000 if bone marrow involvement)Xx_NEWLINE_xXPlatelets >= 50,000/ulXx_NEWLINE_xXPlatelets >= 50,000/mcL in the absence of transfusion support within 7 days prior to determination of eligibilityXx_NEWLINE_xXPlatelets >= 50,000 cells/uL (50 x 10^9/L)Xx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets >= 60,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets >= 60,000/mm^3Xx_NEWLINE_xXPlatelets >= 100000/mclXx_NEWLINE_xXPlatelets >= 50,000/mLXx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets < 50 x 10^9/LXx_NEWLINE_xXPlatelets >= 50,000 (50 x 10^9/L)Xx_NEWLINE_xXPlatelets > 80,000Xx_NEWLINE_xXPlatelets >= 50,000/mLXx_NEWLINE_xXPlatelets > 50,000 (platelet transfusion allowed)Xx_NEWLINE_xXPlatelets >= 50 x 10^3/uLXx_NEWLINE_xXPlatelets >= 125,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets >= 50,000/uL (unless documented bone marrow involvement with lymphoma)Xx_NEWLINE_xXPlatelets >= 50,000/mLXx_NEWLINE_xXPlatelets >= 50,000/mLXx_NEWLINE_xXPlatelets > 50,000Xx_NEWLINE_xXPlatelets count ? 50,000/mm3Xx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 50,000/mLXx_NEWLINE_xXPlatelets > 50,000/uLXx_NEWLINE_xXPlatelets > 50,000/uLXx_NEWLINE_xXPlatelets >= 50 x 10^9/L, unless cytopenias are deemed due to diseaseXx_NEWLINE_xXPlatelets >= 50,000 uLXx_NEWLINE_xXPlatelets >= 80,000/mm^3Xx_NEWLINE_xXPRIOR TO POST-TRANSPLANT IMMUNOTHERAPY: Platelets > 50,000/uLXx_NEWLINE_xXDONOR: Platelets >= 80,000Xx_NEWLINE_xXPlatelets =< 125,000 cells/ul (blood work will be repeated within 2 weeks and if still abnormal, patient will be excluded)Xx_NEWLINE_xXPlatelets > 50,000/mm^3 (without support)Xx_NEWLINE_xXPlatelets (PLT) >= 50,000/uLXx_NEWLINE_xXPlatelets >= 30,000/mm^3Xx_NEWLINE_xXPlatelets of 75KXx_NEWLINE_xXPlatelets >= 125,000/mcLXx_NEWLINE_xXPatients must be appropriate candidates for RFA, with platelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets > 80,000/mcLXx_NEWLINE_xXPlatelets >= 50,000 cells/uL, or >= 30,000/uL if bone marrow is involved by malignancyXx_NEWLINE_xXPlatelets >= 50 X 10^9/LXx_NEWLINE_xXPlatelets ? 50 X 10³/µLXx_NEWLINE_xXPlatelets >= 50.0 x 10^9/LXx_NEWLINE_xXPlatelets > 50,000/mm^3Xx_NEWLINE_xXPlatelets < 50,000/mclXx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets >= 125 x 10^9/L (125,000/mm^3)Xx_NEWLINE_xXPlatelets count ? 100x10E9/LXx_NEWLINE_xXPlatelets >= 90,000/mm^3Xx_NEWLINE_xXPlatelets >= 80,000 x 10^9/LXx_NEWLINE_xXPlatelets > 50,000/uLXx_NEWLINE_xXPlatelets >= 50,000Xx_NEWLINE_xXPlatelets >= 50,000Xx_NEWLINE_xXPlatelets greater than 150,000 cells/mm^3; these results can be within last 60 days from the day of signing informed consentXx_NEWLINE_xXPlatelets >= 50,000/mclXx_NEWLINE_xXPlatelets > 125,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mm^3 or 30,000 (if marrow infiltrated with myeloma; no platelet transfusions are allowed in the 7 days prior to screening)Xx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets > 50,000/uL not supported by transfusionsXx_NEWLINE_xXPatients must have platelets (Plt) >= 50,000/uL; platelet transfusion can be given prior to the start of SGN-35 and during SGN-35 treatment to achieve a target plt >= 50,000/uLXx_NEWLINE_xXPlatelets (Plts) >= 50,000/uLXx_NEWLINE_xXPlatelets >= 50 x 10^3/uLXx_NEWLINE_xXPlatelets >= 60,000/mcL without transfusion support within the past 30 daysXx_NEWLINE_xXPlatelets < 25.000/µL.Xx_NEWLINE_xXPlatelets > 50 K/mcLXx_NEWLINE_xXPlatelets >= 50,000Xx_NEWLINE_xXPlatelets ?50,000/mm3Xx_NEWLINE_xXPlatelets ?50,000/mm3 independent of transfusionXx_NEWLINE_xXPlatelets ?50,000/mm3 independent of transfusionXx_NEWLINE_xXPlatelets > 50,000 cells/mcl (cohort 1)Xx_NEWLINE_xXPlatelets > 50,000 cells/mcl (Cohort 1)Xx_NEWLINE_xXPlatelets > 50,000 cells/mclXx_NEWLINE_xXPlatelets < 125,000/µLXx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets (plts) > 90,000Xx_NEWLINE_xXPlatelets >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement independent of transfusion support in either situationXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets less than 50,000 within 6 months prior to study enrollment orXx_NEWLINE_xXPlatelets (PLTs) >= 40,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mcLXx_NEWLINE_xXPlatelets >= 50,000/mm^3Xx_NEWLINE_xXPlatelets > 50,000/mm^3 without growth factors or transfusionsXx_NEWLINE_xXPlatelets < 50 H K/UL in the past 30 daysXx_NEWLINE_xXPlatelets > 50,000Xx_NEWLINE_xXPlatelets < 50 H K/UL in the past 30 daysXx_NEWLINE_xXPlatelets >= 90,000/mcLXx_NEWLINE_xXPlatelets >= 50 B/L (10^9/L)Xx_NEWLINE_xXPlatelets >= 50,000/uLXx_NEWLINE_xXPlatelets >= 50,000/microliterXx_NEWLINE_xXPlatelets >= 150,000/microliterXx_NEWLINE_xXPlatelets > 50,000/uLXx_NEWLINE_xXWithin 30 days of eligibility confirmation: Platelets >= 50,000/uLXx_NEWLINE_xXTotal bilirubin >1.8, creatinine >2, hemoglobin <10, platelets <50,000, WBC <2,000)Xx_NEWLINE_xXTotal bilirubin >1.5, creatinine >2, hemoglobin <10, platelets <50,000, WBC <2,000Xx_NEWLINE_xXPlatelets >= 150,000/mcLXx_NEWLINE_xXUncorrectable coagulopathy prohibiting biopsy. (INR > 1.5 and/ or platelets < 50,000)Xx_NEWLINE_xXPlatelets < 50 K/mcLXx_NEWLINE_xXPlatelets > 50,000/uLXx_NEWLINE_xXPlatelets < 75K/mcLXx_NEWLINE_xXPlatelets >= 90,000/mm^3Xx_NEWLINE_xXPlatelets < 90,000/mm^3Xx_NEWLINE_xXPlatelets ? 150,000/mcLXx_NEWLINE_xXPlatelets > 50,000Xx_NEWLINE_xXPlatelets >= 150,000/mcLXx_NEWLINE_xXPlatelets >= 80,000/mcLXx_NEWLINE_xX